Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Clinical Study on the Safety and Efficacy of Anti-CD19-CD3E-CAR-T Cells in the Treatment of Relapsed or Refractory Autoimmune Disease

NCT06373081 is registered in ClinicalTrials.gov with Shanghai Changzheng Hospital as lead sponsor.

NCT NCT06373081
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT06373081 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Clinical Study on the Safety and Efficacy of Anti-CD19-CD3E-CAR-T Cells in the Treatment of Relapsed or Refractory Autoimmune Disease
Lead sponsor
Shanghai Changzheng Hospital
Phase
Not applicable
Overall status
Unknown status
Start date
April 20, 2024
Completion date
April 15, 2026
Enrollment
6 (estimated)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

anca associated vasculitis, antiphospholipid syndrome, inflammatory myopathy, sjogren's syndrome, systemic lupus erythematosus (sle), systemic sclerosis